PMID- 12362115
OWN - NLM
STAT- MEDLINE
DCOM- 20021021
LR  - 20220317
IS  - 0894-9115 (Print)
IS  - 0894-9115 (Linking)
VI  - 81
IP  - 10
DP  - 2002 Oct
TI  - Botulinum toxin type A use in piriformis muscle syndrome: a pilot study.
PG  - 751-9
AB  - OBJECTIVE: This study was undertaken to test the hypothesis that intramuscular 
      botulinum toxin type A decreases chronic pain attributed to piriformis muscle 
      syndrome to a greater extent than a similar injection with vehicle (saline) 
      alone. DESIGN: This double-blind, single group, crossover study was performed at 
      an outpatient university clinic. Nine women with chronic buttock, hip, and lower 
      limb pain without evidence of lumbar disk herniation or nerve root impingement on 
      imaging studies participated in the study. The analgesic efficacy of a 
      fluoroscopic/electromyographically guided unilateral intramuscular piriformis 
      injection with 100 units botulinum toxin type A was compared with a similar 
      injection of vehicle alone. Visual analog pain scales (VASs) were used to measure 
      pain intensity, distress, spasm, and interference with activities. RESULTS: No 
      differences in mean VASs were detected between groups at baseline or after 
      injection with vehicle. However, decreases were observed between baseline and 
      post-botulinum toxin type A injection mean VASs, but only in one of four 
      categories (interference with activities). VASs from every time point (days) were 
      also compared with the average baseline VASs. After injection with vehicle, 
      decreases were detected, but only in one of the four categories (distress). In 
      comparison, after injection with botulinum toxin type A, decreases were observed 
      under all VAS categories. CONCLUSIONS: VAS data suggest that intramuscular 
      piriformis injection with 100 units of botulinum toxin type A can reduce pain to 
      a greater extent than similar injections with vehicle alone.
FAU - Childers, Martin K
AU  - Childers MK
AD  - Department of Physical Medicine and Rehabilitation, University of 
      Missouri-Columbia Hospital, 65212, USA.
FAU - Wilson, Daniel J
AU  - Wilson DJ
FAU - Gnatz, Steve M
AU  - Gnatz SM
FAU - Conway, Robert R
AU  - Conway RR
FAU - Sherman, Ashley K
AU  - Sherman AK
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Phys Med Rehabil
JT  - American journal of physical medicine & rehabilitation
JID - 8803677
RN  - 0 (Neuromuscular Agents)
RN  - EC 3.4.24.69 (Botulinum Toxins, Type A)
SB  - IM
MH  - Activities of Daily Living
MH  - Adult
MH  - Botulinum Toxins, Type A/pharmacology/*therapeutic use
MH  - *Buttocks
MH  - Chronic Disease
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Electromyography
MH  - Female
MH  - Fluoroscopy/methods
MH  - H-Reflex
MH  - Humans
MH  - Injections, Intramuscular
MH  - Middle Aged
MH  - Musculoskeletal Diseases/diagnosis/*drug therapy/etiology
MH  - Neuromuscular Agents/pharmacology/*therapeutic use
MH  - Pain/diagnosis/*drug therapy/etiology
MH  - Pain Measurement
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Radiography, Interventional/methods
MH  - Sciatic Nerve
MH  - Syndrome
MH  - Wounds, Nonpenetrating/complications
EDAT- 2002/10/04 04:00
MHDA- 2002/10/22 04:00
CRDT- 2002/10/04 04:00
PHST- 2002/10/04 04:00 [pubmed]
PHST- 2002/10/22 04:00 [medline]
PHST- 2002/10/04 04:00 [entrez]
AID - 00002060-200210000-00006 [pii]
AID - 10.1097/00002060-200210000-00006 [doi]
PST - ppublish
SO  - Am J Phys Med Rehabil. 2002 Oct;81(10):751-9. doi: 
      10.1097/00002060-200210000-00006.